Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

 Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Shots:

  • Glenmark to receive up front, license fee and royalties on sales and is responsible to manufacture and supply Remogliflozin. Torrent to get rights to commercialize Remogliflozin under the trademark Zucator in India
  • In Apr’2019, Remogliflozin has received CDSCO’s approval following the completion of its P-III studies assessing Remogliflozin vs Dapagliflozin for the treatment of type 2 diabetes mellitus in adults
  • Remogliflozin is the SGLT2 inhibitor act by blocking glucose reabsorption in the kidney further causes the elimination of blood glucose through urine and has been evaluated in 26+ clinical studies globally

Click here to read full press release/ article | Ref: Glenmark | Image: For Press Release

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post